Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
Clinical Trials
World-first experimental cancer treatment paves way for clinical trial
A peer-reviewed paper detailing the experimental cancer treatment developed by Professor Georgina Long AO, University of Sydney medical oncologist and Medical Director of the Melanoma Institute Australia, has today been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases.
Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
Evaxion Biotech has completed subject dosing in the Phase II trial of its personalised peptide-based cancer vaccine, EVX-01, for the treatment of advanced melanoma, also referred to as skin cancer.